Skip to main content

Table 2 Patients characteristics: Arm A: erlotinib followed by docetaxel plus gemcitabine (DG) after progression; Arm B: DG followed by erlotinib after progression (* no significant difference, ** p = 0.013)

From: Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

  Arm A Arm B
  n = 48 n = 51
Age mean (years) 76 ± 5 76 ± 4*
Gender male (%) 29 (60 %) 30 (59 %)*
Smoker 6 (13 %) 8 (16 %)*
Current 26 (54 %) 25 (49 %)
Former 15 (31 %) 15 (29 %)
Never smoker 1 (2 %) 3 (6 %)
Unknown   
Performance status 22 (47 %) 21 (41 %)*
0 21 (45 %) 28 (55 %)
1 4 (9 %) 2 (4 %)
2   
Stage 6 (13 %) 4 (8 %)*
IIIB 42 (87 %) 47 (92 %)
IV   
Histology 11 (23 %) 8 (16 %)**
Squamous cell 28 (58 %) 29 (57 %)
Adenocarcinoma 9 (19 %) 14 (28 %)
Undifferentiated   
Second line treatment 29 (60 %) 24 (47 %)**